2017 – Biz News Today

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease

On December 20, 2017

Business News

Original Source

TARIS and Bristol-Myers Squibb Announce Clinical Trial Collaboration

On December 20, 2017

Business News

Original Source

Bristol-Myers Squibb to Announce Results for Fourth Quarter 2017 on February 5th

On December 19, 2017

Business News

Original Source

Norwegian Cruise Line Announces Summer 2019 Itineraries

On December 19, 2017

Business News

Norwegian Cruise Line today revealed the fleet’s exciting lineup ofRead More

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Yervoy (ipilimumab) for the Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

On December 18, 2017

Business News

Original Source

Bristol-Myers Squibb Named One of America’s Most JUST Companies in 2017 By Forbes and JUST Capital

On December 14, 2017

Business News

Original Source

Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment

On December 13, 2017

Business News

Original Source

U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma and Grants Priority Review

On December 13, 2017

Business News

Original Source

Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma

On December 11, 2017

Business News

Original Source

Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

On December 9, 2017

Business News

Original Source

Bristol-Myers Squibb Announces Dividend Increase

On December 7, 2017

Business News

Original Source

U.S. Food and Drug Administration Lifts Partial Clinical Holds on Two Opdivo-based Combination Studies in Multiple Myeloma

On December 5, 2017

Business News

Original Source

Bristol-Myers Squibb and Pfizer Alliance Urge People to ‘Tune in to AFib, Take Note of Stroke Risk’

On December 5, 2017

Business News

Original Source

Cruising with Norwegian: There’s an App for That

On December 4, 2017

Business News

Norwegian Cruise Line announced today the introduction of the nextRead More

CheckMate -078, a Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial with Predominantly Chinese Patients, Stopped Early for Demonstrating Superior Overall Survival

On November 30, 2017

Business News

Original Source

Bristol-Myers Squibb to Take Part at the Citi 2017 Global Healthcare Conference

On November 30, 2017

Business News

Original Source

Bristol-Myers Squibb to Present New Data Across a Broad Range of Blood Cancers at the 59th Annual Meeting & Exposition of the American Society of Hematology

On November 29, 2017

Business News

Original Source

Norwegian Cruise Line Names Top On-Air Personality, Elvis Duran, as Godfather for Its Newest Ship, Norwegian Bliss

On November 29, 2017

Business News

Norwegian Cruise Line announced today that Elvis Duran, nationally syndicatedRead More

Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Neutrolis, Remora Therapeutics

On November 28, 2017

Business News

Original Source

European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma

On November 28, 2017

Business News

Original Source